Antiemetic Control with Palonosetron in Patients with Gastrointestinal Cancer Receiving a Fluoropyrimidine-Based Regimen in Addition to Either Irinotecan or Oxaliplatin: A Retrospective Study
Authors:
- Marlo BlazerMBMarlo Blazer
- Gary PhillipsGPGary Phillips
- Joshua ReardonJRJoshua Reardon
- David EfriesDEDavid Efries
- Yahna SmithYSYahna Smith
- Lynn WeatherbyLWLynn Weatherby
- Kim JuergensKJKim Juergens
- Jeffrey RoseJRJeffrey Rose
- Niesha GriffithNGNiesha Griffith
- Tanios Bekaii-SaabTBTanios Bekaii-Saab
- 18 July 2012
- journal article
- clinical trial
- Published by S. Karger AG in Oncology
- Vol. 83 (3) , 135-140
Abstract
Background: For moderately emetogenic chemotherapy, palonosetron (PALO) is reported to provide complete control of chemotherapy-induced nausea and vomiting (CINV) in 69% of patients. Prior to August 2009, our gastrointestinal (GI) cancer patients receiving the moderately emetogenic compounds oxaliplatin or irinotecan plus a fluoropyrimidine regimen received ondansetron and dexamethasone orally on day 1 of chemotherapy for CINV prevention. Beginning in August of 2009, ondansetron was replaced by PALO 0.25 mg (intravenous push). Methods: This is a single-institution retrospective study of GI cancer patients who received oxaliplatin or irinotecan plus a fluoropyrimidine. Failure of an antiemetic regimen was defined as grade ≥1 vomiting or grade ≥2 nausea (Common Terminology Criteria for Adverse Events, version 3) on days 1 through 5 following chemotherapy. Patients were divided for analysis into pre-PALO and post-PALO cohorts. Fisher’s exact test compared cohort differences. Results: A total of 305 patients were included in the study, with 157 patients in the pre-PALO cohort and 148 in the post-PALO cohort. For all patients, the risk of antiemetic failure was reduced from 50.3% [95% confidence interval (CI) 42.2–58.4%] to 28.4% (95% CI 21.3–36.4%) with PALO. This reduction in the relative risk of antiemetic failure was observed in all subgroups. Conclusion: The addition of PALO may provide increased control of CINV for the moderately emetogenic regimens of oxaliplatin or irinotecan plus a fluoropyrimidine in GI cancer patients.Keywords
This publication has 17 references indexed in Scilit:
- American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006Journal of Clinical Oncology, 2006
- Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonistCancer, 2003
- Clinical Science Review: Comparative Review of 5-HT3Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and VomitingCancer Investigation, 2000
- Effect of postchemotherapy nausea and vomiting on health-related quality of lifeSupportive Care in Cancer, 1997
- Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1997
- The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitroBritish Journal of Pharmacology, 1995
- Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapyThe Lancet, 1991
- Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic modelCancer, 1989
- Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population.Journal of Clinical Oncology, 1989
- On the receiving end—patient perception of the side-effects of cancer chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1983